The Emerging “N-of-1” Model:Clinical Relevance of Individualized Tumor Profiling Grows in Research Programs
The recent approval of the second-generation proteasome inhibitor carfilzomib by the FDA comes nine years after the initial approval of bortezomib, the first-in-class drug of its type.
- A Network of Your PeersView more >>
Most Popular Right Now
Gary M. Kirsh, MD, Earl L. Walz, and Pamela Skurkay discuss the integration of the autologous cellular immunotherapy sipuleucel-T (Provenge) into clinical practice for men with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer. View Now